Press releases

Invitation to presentation of BioArctic’s Interim Report for the period January – September 2021 on October 21 at 9.30 a.m. CET

October 11, 2021 - Other press release

Stockholm, Sweden, October 11, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s Interim Report for the period January – September 2021 ...

Eisai initiates rolling submission for the US FDA Biologics license application of lecanemab for early Alzheimer’s disease under the accelerated approval pathway

September 28, 2021 - Regulatory press release

Stockholm, September 28, 2021 - BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that they have initiated a rolling submission to the U.S. ...

New data presented at MDS Congress of ABBV-0805 in Parkinson’s disease

September 10, 2021 - Other press release

Stockholm, September 10, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will present new preclinical data for the investigational anti-?-synuclein antibody ABBV-0805 at the International ...

Eisai presented latest data from the lecanemab clinical program at AAIC 2021

July 30, 2021 - Other press release

Stockholm, July 30, 2021 - BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai held several presentations at the Alzheimer’s Association International Conference (AAIC) in Denver, ...

Latest data on lecanemab to be presented at Alzheimer’s Association International Conference (AAIC)

July 21, 2021 - Other press release

Stockholm, July 21, 2021 - BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will hold several presentations at the Alzheimer’s Association International Conference (AAIC) to ...

Interim Report for the period April – June 2021

July 9, 2021 - Regulatory press release

FDA grants Breakthrough Therapy designation for lecanemab Events during the second quarter 2021 The US Food and Drug Administration (FDA) granted Breakthrough Therapy designation for lecanemab ...

FDA grants Breakthrough Therapy designation for lecanemab in Alzheimer’s disease

June 23, 2021 - Regulatory press release

Stockholm, 23 June 2021 - BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the U.S. Food and Drug Administration (FDA) has granted ...

BioArctic receives patent in Japan for new antibodies targeting Alzheimer’s disease

May 11, 2021 - Other press release

  Stockholm, May 11, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the Japanese Patent Office (JPO) has allowed the company’s ...

Report from annual general meeting in BioArctic AB (publ)

May 6, 2021 - Regulatory press release

Stockholm, Sweden, May 6, 2021 - BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today held its Annual General Meeting. Due to the continued spread of the ...

Interim Report for the period January – March 2021

April 21, 2021 - Regulatory press release

New data continues to strengthen lecanemab

Lecanemab (BAN2401) Phase 2b study in early Alzheimer’s disease published in peer-reviewed journal, Alzheimer’s Research & Therapy

April 20, 2021 - Other press release

Stockholm April 20, 2021 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced the publication of an article, A Randomized, Double-Blind Phase 2b ...

Invitation to presentation of BioArctic’s Interim Report for the period January – March 2021 on April 21 at 9.30 a.m. CET

April 15, 2021 - Other press release

Stockholm, Sweden, April 15, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B)  will publish the company’s Interim Report for the period January – March 2021 ...

Notice of Annual General Meeting in BioArctic AB (publ)

April 7, 2021 - Regulatory press release

The shareholders in BioArctic AB (publ), corporate identity number 556601-2679 (the “Company” or “BioArctic”) are hereby summoned to the Annual General Meeting to be held on ...

BioArctic publishes the Annual Report for 2020

March 31, 2021 - Regulatory press release

Stockholm March 31, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Swedish version of the 2020 Annual Report has been published. 

BioArctic and Eisai presented latest data regarding lecanemab at AD/PD 2021

March 15, 2021 - Other press release

Stockholm, March 15, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced data on the drug candidate lecanemab (BAN2401), which were presented by the ...

Latest lecanemab data to be presented at the AD/PD™ congress

March 5, 2021 - Other press release

Stockholm, March 5, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company and its collaboration partner Eisai will both present data ...

The Nomination Committee’s proposal for the election of board members in BioArctic AB

February 12, 2021 - Regulatory press release

Stockholm February 12, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Nomination Committee for BioArctic AB (publ) presents the following proposals ...

Interim Report for the period January – December 2020

February 4, 2021 - Regulatory press release

New data provides further support for BAN2401 (lecanemab)  

Eisai increases the number of participants in Clarity AD study

February 3, 2021 - Other press release

Stockholm, February 3, 2021 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have increased the participant target number by approximately ...

BioArctic receives European patent for new antibodies targeting Alzheimer’s disease

January 27, 2021 - Other press release

Stockholm, January 27, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant ...

Invitation to presentation of BioArctic’s Full Year Report for the period January – December 2020 on February 4 at 9.30 a.m. CET

January 26, 2021 - Other press release

Stockholm, Sweden, January 26, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s Full Year Report for the period January – December ...